Skip to Content

About us

Our Story

Vision

We aim to provide clinicians, microbiologists, pharmacists and hospital teams with the tools and support they need to treat difficult bacterial infections effectively. Our team works every day to make high-quality, clinically supported phage therapy available to patients who need alternatives.

Mission

To make personalised phage therapy accessible and clinically reliable, enabling healthcare professionals to address difficult-to-treat infections when standard options fail. From diagnostics to therapy and knowledge sharing, Inteliphage supports hospitals with the expertise and tools needed to deliver safe, high-quality care.

Ambition

To make phage therapy practical at hospital level by offering a complete in-house workflow that removes today’s logistical barriers. We aim to shorten phage matching from days or weeks to hours and to provide hospital pharmacists with reliable products made to high quality standards.

Our Executive Team

Charles Perrard, CEO

Over 20 years experience in company creation, development & management in various industries, especially e-health and medical devices sector.

Joined Inteliphage in 2025 after having served as Principal at Kearney in Europe and as CEO and co-founder of the start-up studio Sparkling Partners. 

Guillaume de Viron, COO

Over 20 years of finance experience at biotech companies OncoDNA, Masthercell, Univercells & IMCYSE among others.

Joined Inteliphage in June 2021 after having occupied several advisor and part-time CFO positions at biotech companies

Gunther Vanwezer, CBO

More than 25 years in MedTech & Life Sciences Industry, focused on go-to-market strategy, market access & pricing along with company building

Joined Inteliphage in 2022 after key roles in at Terumo BCT, Thermo Fisher Scientific and Organ Recovery Systems where he was Managing Director EMEIA and built the company's brand & business. 

Johan Quintens, CSO

Johan has been with Inteliphage since its start in 2018. He brings 30 years of experience in the pharmaceutical industry across research, CSO roles and general management. 

He holds eight patents in probiotic and phage technologies. As CSO, he leads Inteliphage’s scientific strategy and translates phage expertise into clinically usable solutions.  

We are always open for collaborations

Join us in our mission to provide phage therapy to last-hope patients.